Q2 2023
Released Aug 10, 2023, before the open
10-Q filed Aug 10, 2023, 41 days after period end · 0001493152-23-027460
Q2 2023 · 10-Q
Revenue$0.00$0.00 derived−100.0% vs Q2 2022−100.0% vs Q1 2023
Net Income-$3.55M-$3.55M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.68-$0.68 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$3,955,605N/M
Operating Cash Flowderived-$3,309,597N/M
Free Cash Flowderived-$3,309,597N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | $500.00K | — | — |
| Net Income | -$3.55M | -$2.63M | -$6.81M | -$6.37M |
| EPS Diluted | -$0.68 | -$0.61 | -$0.08 | -$0.13 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR